Crowley, TX, United States of America

Debra L Fleenor

USPTO Granted Patents = 2 

Average Co-Inventor Count = 2.9

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2008-2010

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Debra L Fleenor: Innovator in Glaucoma Treatment

Introduction

Debra L Fleenor is a prominent inventor based in Crowley, TX (US). She has made significant contributions to the field of ophthalmology, particularly in the treatment of glaucoma. With a total of 2 patents, her work focuses on innovative methods to lower intraocular pressure and provide neuroprotection.

Latest Patents

Fleenor's latest patents include groundbreaking compositions and methods for treating glaucoma. One patent discusses the use of inhibitors of Jun N-terminal kinases (JNK) to lower intraocular pressure (IOP) and provide neuroprotection. This invention highlights the potential of these inhibitors in managing glaucoma effectively. Another patent presents a method for lowering IOP and providing neuroprotection by administering agents that regulate the activity and expression of connective tissue growth factor (CTGF). This unique approach aims to treat glaucomatous retinopathies and optic neuropathies.

Career Highlights

Debra L Fleenor is associated with Alcon, Inc., a leading company in eye care. Her work at Alcon has allowed her to focus on developing innovative solutions for eye health, particularly in the area of glaucoma treatment. Her dedication to research and development has positioned her as a key figure in her field.

Collaborations

Fleenor has collaborated with notable colleagues, including Iok-Hou Pang and Allan R Shepard. These partnerships have contributed to her success and the advancement of her research in glaucoma treatment.

Conclusion

Debra L Fleenor's contributions to glaucoma treatment through her innovative patents and collaborations highlight her importance in the field of ophthalmology. Her work continues to pave the way for new therapeutic approaches to managing this challenging condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…